



wherein ring A, fused to the ring containing X and N, represents a 5-6 membered cyclic ring optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C<sub>1-12</sub>alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, C<sub>1-12</sub>alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-12</sub>alkyl, amino, acylamino, C<sub>1-12</sub>alkyl-amino, arylamino, aralkylamino, aminoC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>alkoxyC<sub>1-12</sub>alkyl, aryloxyC<sub>1-12</sub>alkyl, aralkoxyC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkylthio, thioC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, halogen, perhalomethyl, C<sub>1-6</sub>alkoxy or amino optionally substituted with one or more C<sub>1-6</sub>alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

ring B, fused to the ring containing X and N, represents a 5-6 membered cyclic ring optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C<sub>1-12</sub>alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, C<sub>1-12</sub>alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-12</sub>alkyl, amino, acylamino, C<sub>1-12</sub>alkyl-amino, arylamino, aralkylamino, aminoC<sub>1-12</sub>alkyl,

C<sub>1-12</sub>alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>alkoxyC<sub>1-12</sub>alkyl, aryloxyC<sub>1-12</sub>alkyl, aralkoxyC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkylthio, thioC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, halogen, perhalomethyl, C<sub>1-6</sub>alkoxy or amino optionally substituted with one or more C<sub>1-6</sub>alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

X is -O-(CHR<sup>9</sup>)-, -S-(CHR<sup>9</sup>)-, -(NR<sup>9</sup>)-CH<sub>2</sub>-, -CH<sub>2</sub>-(SO)-, -CH<sub>2</sub>-(SO<sub>2</sub>)-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, wherein R<sup>9</sup> is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C<sub>1-12</sub>alkyl-amino, arylamino, aralkylamino, aminoC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C<sub>1-12</sub>alkoxyC<sub>1-12</sub>alkyl, aryloxyC<sub>1-12</sub>alkyl, aralkoxyC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkylthio, thioC<sub>1-12</sub>alkyl, C<sub>1-12</sub>alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, halogen, C<sub>1-6</sub>alkoxy, amino optionally substituted with one or more C<sub>1-6</sub>alkyl, perhalomethyl or aryl;

Q is -O-, -S-, >SO<sub>2</sub>, >NR<sup>13</sup>, wherein R<sup>13</sup> is hydrogen or C<sub>1-6</sub>alkyl,

Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C<sub>1-6</sub>alkyl or aryl;

R<sup>5</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>alkoxy, C<sub>1-12</sub>alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,

R<sup>6</sup> represents hydrogen, hydroxy, halogen, C<sub>1-12</sub>alkoxy, C<sub>1-12</sub>alkyl, C<sub>4-12</sub>-alkenynyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,

$R^7$  represents hydrogen,  $C_{1-12}$ alkyl,  $C_{4-12}$ -alkenynyl,  $C_{2-12}$ -alkenyl,  $C_{2-12}$ -alkynyl, aryl, aralkyl,  $C_{1-12}$ alkoxy $C_{1-12}$ alkyl,  $C_{1-12}$ alkoxycarbonyl, aryloxycarbonyl,  $C_{1-12}$ alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups[;], optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

$R^8$  represents hydrogen,  $C_{1-12}$ alkyl,  $C_{4-12}$ -alkenynyl,  $C_{2-12}$ -alkenyl,  $C_{2-12}$ -alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

Y represents oxygen, sulphur or  $NR^{10}$ , where  $R^{10}$  represents hydrogen,  $C_{1-12}$ alkyl, aryl, hydroxy $C_{1-12}$ alkyl or aralkyl groups or when Y is  $NR^{10}$ ,  $R^8$  and  $R^{10}$  may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more  $C_{1-6}$ alkyl;

n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;  
or a pharmaceutically acceptable salt thereof.

2. (Amended) The compound according to claim 1, wherein ring A, fused to the ring containing X and N, represents a 5-6 membered cyclic ring optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or  $C_{1-7}$ alkyl,  $C_{4-7}$ -alkenynyl,  $C_{2-7}$ -alkenyl,  $C_{2-7}$ -alkynyl,  $C_{1-7}$ alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy $C_{1-7}$ alkyl, amino, acylamino,  $C_{1-7}$ alkyl-amino, arylamino, aralkylamino, amino $C_{1-7}$ alkyl,  $C_{1-7}$ alkoxy $C_{1-7}$ alkyl, aryloxy $C_{1-7}$ alkyl, aralkoxy $C_{1-7}$ alkyl,  $C_{1-7}$ alkylthio, thio $C_{1-7}$ alkyl,  $C_{1-7}$ alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,  $-COR^{11}$ , or  $-SO_2R^{12}$ , wherein  $R^{11}$  and  $R^{12}$  independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more  $C_{1-6}$ alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

7. (Amended) The compound according to claim 1, wherein ring B, fused to the ring containing X and N, represents a 5-6 membered cyclic ring optionally

substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C<sub>1-7</sub>alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, C<sub>1-7</sub>alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC<sub>1-7</sub>alkyl, amino, acylamino, C<sub>1-7</sub>alkyl-amino, arylamino, aralkylamino, aminoC<sub>1-7</sub>alkyl, C<sub>1-7</sub>alkoxyC<sub>1-7</sub>alkyl, aryloxyC<sub>1-7</sub>alkyl, aralkoxyC<sub>1-7</sub>alkyl, C<sub>1-7</sub>alkylthio, thioC<sub>1-7</sub>alkyl, C<sub>1-7</sub>alkoxycarbonyl-amino, aryloxy carbonylamino, aralkoxy carbonylamino, -COR<sup>11</sup>, or -SO<sub>2</sub>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C<sub>1-6</sub>alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

16. (Amended) The compound according to claim 1 wherein Q is -O- or -S-.

18. (Amended) The compound according to claim 1 wherein Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C<sub>1-6</sub>alkyl or aryl;

R<sup>5</sup> represents hydrogen, hydroxy, halogen, C<sub>1-7</sub>alkoxy, C<sub>1-7</sub>alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl; or R<sup>5</sup> forms a bond together with R<sup>6</sup>,

R<sup>6</sup> represents hydrogen, hydroxy, halogen, C<sub>1-7</sub>alkoxy, C<sub>1-7</sub>alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl; or R<sup>6</sup> forms a bond together with R<sup>5</sup>,

R<sup>7</sup> represents hydrogen, C<sub>1-7</sub>alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, aryl, aralkyl, C<sub>1-7</sub>alkoxyC<sub>1-7</sub>alkyl, C<sub>1-7</sub>alkoxycarbonyl, aryloxy carbonyl, C<sub>1-7</sub>alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R<sup>8</sup> represents hydrogen, C<sub>1-7</sub>alkyl, C<sub>4-7</sub>-alkenynyl, C<sub>2-7</sub>-alkenyl, C<sub>2-7</sub>-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl;

Y represents oxygen, sulphur or NR<sup>10</sup>, where R<sup>10</sup> represents hydrogen, C<sub>1-7</sub>alkyl, hydroxyC<sub>1-7</sub>alkyl;

n is an integer ranging from 2 to 3 and m is an integer ranging from 0 to 1.

23. (Amended) The compound according to claim 1 wherein A is 5 membered cyclic ring containing S.

A6  
24. (Amended) The compound according to claim 1 wherein B is 5 membered cyclic ring containing S.

---

26. (Amended) The compound according to claim 1 wherein n is 2.

27. (Amended) The compound according to claim 1 wherein Q is -O-.

28. (Amended) The compound according to claim 1 wherein m is 1.

A7  
29. (Amended) The compound according to claim 1 wherein Ar is phenylene.

30. (Amended) The compound according to claim 1 wherein R<sup>6</sup> is H.

31. (Amended) The compound according to claim 1 wherein R<sup>7</sup> is ethyl.

32. (Amended) The compound according to claim 1 wherein Y is oxygen.

33. (Amended) The compound according to claim 1 wherein R<sup>8</sup> is H.

---

36. (Amended) A pharmaceutical composition comprising as an active ingredient, the compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

---

Sub  
C2  
43. (Amended) A method for the treatment of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

---

44. (Amended) A method for the treatment of diabetes, the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

---

Please add the following new claims :

50. (New) The pharmaceutical composition of claim 36, wherein the compound is in a unit dosage form in the amount of between 0.05 to about 100 mg.

51. (New) The pharmaceutical composition of claim 37, wherein the compound is in a unit dosage form in the amount of between 0.1 to about 50 mg.

52. (New) The method of claim 44, wherein the compound is administered by oral, nasal, transdermal, pulmonary, or parenteral administration.

53. (New) A method for the treatment of obesity, the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

54. (New) The method of claim 53, wherein the compound is administered by oral, nasal, transdermal, pulmonary, or parenteral administration.